Angioedema Newswire

Comprehensive Real-Time News Feed for Angioedema.

Results 1 - 12 of 12 in Angioedema

  1. Spark Therapeutics Appoints Industry Leaders Lars Ekman and Vin Milano to Board of DirectorsRead the original story

    Jun 25, 2014 | Hispanic Business

    ... the lead product was Cinryze, approved and commercially available in the U.S. for the prevention of hereditary angioedema attacks and in for both the treatment and prevention of hereditary angioedema attacks, a rare disease. Vin joined the company ...

    Comment?

  2. Stocks with implied volatility below IV index mean; ZQK HSHRead the original story

    May 27, 2014 | Theflyonthewall.com

    ... $1.81, or 27.42%, to $8.41 after another drug company, BioCryst (BCRX), reported positive data on its inherited angioedema treatment. In a note to investors earlier today, research firm Jefferies wrote that BioCryst's data bodes well for Dyax's own ...

    Comment?

  3. Stocks with implied volatility below IV index mean; ZQK HSHRead the original story w/Photo

    May 23, 2014 | Theflyonthewall.com

    ... $1.81, or 27.42%, to $8.41 after another drug company, BioCryst (BCRX), reported positive data on its inherited angioedema treatment. In a note to investors earlier today, research firm Jefferies wrote that BioCryst's data bodes well for Dyax's own ...

    Comment?

  4. Durata Therapeutics says data from DISCOVER subject of NEJM articleRead the original story

    Jun 4, 2014 | Theflyonthewall.com

    ... $1.81, or 27.42%, to $8.41 after another drug company, BioCryst (BCRX), reported positive data on its inherited angioedema treatment. In a note to investors earlier today, research firm Jefferies wrote that BioCryst's data bodes well for Dyax's own ...

    Comment?

  5. Dyax announces dosing of first subject in DX-2930 Phase 1b TrialRead the original story

    May 27, 2014 | Theflyonthewall.com

    ... $1.81, or 27.42%, to $8.41 after another drug company, BioCryst (BCRX), reported positive data on its inherited angioedema treatment. In a note to investors earlier today, research firm Jefferies wrote that BioCryst's data bodes well for Dyax's own ...

    Comment?

  6. BioCryst data has favorable read through for Dyax, says JefferiesRead the original story

    May 27, 2014 | Theflyonthewall.com

    ... $1.81, or 27.42%, to $8.41 after another drug company, BioCryst (BCRX), reported positive data on its inherited angioedema treatment. In a note to investors earlier today, research firm Jefferies wrote that BioCryst's data bodes well for Dyax's own ...

    Comment?

  7. Natural Urticaria & Angioedema Treatment System Review - Discover...Read the original story

    May 20, 2014 | PRWeb

    Natural Urticaria & Angioedema Treatment system, created by Gary M. Levin, is a brand new program that delivers to urticaria sufferers natural tips to get rid of their problem quickly.

    Comment?

  8. A safe and effective treatment for life-threatening angioedema attacks in the emergency departmentRead the original story

    May 16, 2014 | Medical News Today

    In angioedema , patients experience a rapid swelling of the skin and subcutaneous tissues - which, in some cases, can lead to airway obstruction and suffocation.

    Comment?

  9. Natural Urticaria And Angioedema Treatment Review Shows How to Treat Hives Effectively - Vinaf.comRead the original story

    Mar 25, 2014 | PRWeb

    Natural Urticaria And Angioedema Treatment created by Dr.Gary M Levin is the latest program that teaches people how to stop their urticaria and angioedema.

    Comment?

  10. Why Dyax Corp. Shares DippedRead the original story

    Mar 14, 2014 | The Motley Fool

    ... notes that it's undertaking this offering in order to further the clinical research of DX-2930 for hereditary angioedema as well as research other PKM angioedema disorders. Now what: What we're seeing here is possibly the most visible risk factor of ...

    Comment?

  11. New Sources Of Revenue And Profitability Are In The Future For DyaxRead the original story

    Mar 4, 2014 | Seeking Alpha

    ... to market in late 2009. KALBITOR is a drug that treats potentially life threatening attacks of acute hereditary angioedema (HAE). HAE is a rare disease of the immune system, where patients experience a painful and severe swelling of skin. This can ...

    Comment?

  12. BRIEF-Pharming and Salix say FDA extended PDUFA date for angioedema drug RuconestRead the original story

    Feb 23, 2014 | Reuters

    ... for drug Ruconest * FDA extends date to July 16, 2014 * Cos U.S. marketing approval of Ruconest that treats acute angioedema attacks in patients with hereditary angioedema We welcome comments that advance the story through relevant opinion, ...

    Comment?